CHARENTON-LE-PONT, France—Essilor yesterday announced that the U.S. Food and Drug Administration (FDA) has granted “Breakthrough Device” designation to its Essilor Stellest spectacle lens, the company’s new generation lens developed to correct myopia and slow down the progression of myopia in children. The designation of the Essilor’s Stellest spectacle lens as a “Breakthrough Device” by the FDA, that will lead to further U.S. research and FDA review, builds on the publication of groundbreaking two-year results of an ongoing three-year clinical trial, in China, in myopic children. Read More